SWOG clinical trial number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Open
Phase
Abbreviated Title
Randomized ph III study of Nivo + chemo-immunotherapy for newly dx primary mediastinal B-lymph
Status Notes
CTSU/ANHL1931 was temporarily closed to accrual on 6/24/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
CTSU/ANHL1931 has been endorsed and activated by SWOG, effective 7/15/21. CTSU/ANHL1931 was activated by Children's Oncology Group, effective 6/7/21.
Activated
06/07/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Lymphoma
Treatment
Cyclophosphamide
Prednisone
Vincristine
Doxorubicin
Etoposide
Rituximab
Nivolumab
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
S2207
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2114
A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/ANHL1931
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Research Committee(s)
Lymphoma
Activated
06/07/2021
Open
Phase